logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Sectors
MNPR
Monopar Therapeutics Inc.
111.93
1 x 113.21
1 x 111.95
bid
ask
+
0.04
0.04%
1 @ 07:30 PM
111.50 -0.43 (0.38%)
Ytd71.41%
1y227.76%
106.75
day range
112.97
32.77
52 week range
124.82
Open110.70Prev Close111.89Low106.75High112.97Mkt Cap751.29M
Vol141.85KAvg Vol218.61KEPS-2.20P/EN/AForward P/E-10.17
Beta1.10Short Ratio0.15Inst. Own24.47%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-1250-d Avg105.83200-d Avg74.241yr Est27.33

MNPR News

Monopar Therapeutics (NASDAQ:MNPR) and Regenicin (OTCMKTS:RGIN) Head-To-Head Contrast
defenseworld.net
Monopar Therapeutics (NASDAQ:MNPR) and Regenicin (OTCMKTS:RGIN) Head-To-Head Contrast

Regenicin (OTCMKTS:RGIN - Get Free Report) and Monopar Therapeutics (NASDAQ: MNPR - Get Free Report)

Monopar Appoints Jeffrey D. Kent, M.D.
globenewswire.com
Monopar Appoints Jeffrey D. Kent, M.D.

WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compa

Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'
seekingalpha.com
Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'

Monopar Therapeutics (MNPR) remains a "Strong Buy," driven by exclusive license rights to ALXN1840 f

This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
benzinga.com
This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. STU
benzinga.com
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128

Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and

benzinga.com
Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral, Raises Price Target to $119

Cantor Fitzgerald analyst Kristen Kluska downgrades Monopar Therapeutics (NASDAQ:MNPR) from Overw

Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More
247wallst.com
Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies

Wall Street analysts made bold moves Thursday, slashing targets on some names while dramatically upg
benzinga.com
BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133

BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises t
benzinga.com
Monopar Therapeutics Q2 EPS $(0.62) Misses $(0.56) Estimate

Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.62) per share which missed the a

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

WILMETTE, Ill., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compa
benzinga.com
HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $125

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics (NASDAQ:MNPR)

benzinga.com
Monopar Therapeutics Begins Rolling Submission Of FDA New Drug Application For ALXN1840 Albumin Trip

The FDA has authorized Monopar to submit the NDA on a rolling basis, allowing completed sections of

Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
globenewswire.com
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease

WILMETTE, Ill., July 22, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compa

Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
globenewswire.com
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Boa

WILMETTE, Ill., July 20, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compa

Monopar Therapeutics: ALXN1840's Bull Case Has Improved
seekingalpha.com
Monopar Therapeutics: ALXN1840's Bull Case Has Improved

Monopar Therapeutics has evolved from early radiopharma assets into a more concrete bet with ALXN184
benzinga.com
Monopar Says FDA Grants Rare Pediatric Disease Designation To ALXN1840, Late-Stage Candidate For Tre

Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-sta

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
globenewswire.com
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment

WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compa
benzinga.com
BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $117

BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises t
benzinga.com
HC Wainwright & Co. Reiterates Buy on Monopar Therapeutics, Maintains $105 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Monopar Therapeutics (NASDAQ:MNPR)
benzinga.com
Monopar Therapeutics To Present New Analyses From Phase 3 FoCus Randomized Clinical Trial Of ALXN184

Key findings presented at EAN 2026:In the subset of patients with neurologic symptoms at baseline fr

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
globenewswire.com
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Globa

WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compa

12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular sessi

Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade
zacks.com
Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade

The mean of analysts' price targets for Monopar Therapeutics (MNPR) points to an 88.9% upside in the

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
globenewswire.com
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Impr

WILMETTE, Ill., June 01, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compa
benzinga.com
Monopar Therapeutics Publishes Phase 2 Study Demonstrating ALXN1840 Improves Copper Balance In Pati

Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-sta

Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
globenewswire.com
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper

WILMETTE, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compan

Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

WILMETTE, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Compan

Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
globenewswire.com
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Dise

WILMETTE, Ill. , April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Com
benzinga.com
Monopar Therapeutics Q4 EPS $(0.61) Misses $(0.54) Estimate

Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.61) per share which missed the a

Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
globenewswire.com
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Compan

Monopar Therapeutics Inc. $MNPR Shares Acquired by Ally Bridge Group NY LLC
defenseworld.net
Monopar Therapeutics Inc. $MNPR Shares Acquired by Ally Bridge Group NY LLC

Ally Bridge Group NY LLC increased its position in shares of Monopar Therapeutics Inc. (NASDAQ: MNPR

Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
globenewswire.com
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as

WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopa
benzinga.com
BTIG Reiterates Buy on Monopar Therapeutics, Maintains $104 Price Target

BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintai
benzinga.com
BTIG Reiterates Buy on Monopar Therapeutics, Maintains $104 Price Target

BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintai
benzinga.com
BTIG Reiterates Buy on Monopar Therapeutics, Maintains $104 Price Target

BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintai
benzinga.com
Morgan Stanley Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Ta

Morgan Stanley analyst Maxwell Skor initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with
benzinga.com
The Year-End 2025 Biotech Rally And What It Means For 2026

What Awaits These 4 Biotech Stocks That More Than Doubled in 2025
zacks.com
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025

IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins l

This Home Depot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
benzinga.com
This Home Depot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
benzinga.com
Raymond James Downgrades Monopar Therapeutics to Outperform, Lowers Price Target to $123

Raymond James analyst Chris Raymond downgrades Monopar Therapeutics (NASDAQ:MNPR) from Strong Buy
benzinga.com
Chardan Capital Maintains Buy on Monopar Therapeutics, Maintains $100 Price Target

Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and ma
benzinga.com
Monopar Therapeutics Q3 EPS $(0.48) Misses $(0.45) Estimate

Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.48) per share which missed the a
benzinga.com
Chardan Capital Maintains Buy on Monopar Therapeutics, Raises Price Target to $100

Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and ra
benzinga.com
Leerink Partners Initiates Coverage On Monopar Therapeutics with Outperform Rating, Announces Price

Leerink Partners analyst Joseph Schwartz initiates coverage on Monopar Therapeutics (NASDAQ:MNPR)

This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
benzinga.com
This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For

benzinga.com
Barclays Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target o

Barclays analyst Etzer Darout initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Ove
benzinga.com
Raymond James Maintains Strong Buy on Monopar Therapeutics, Raises Price Target to $142

Raymond James analyst Chris Raymond maintains Monopar Therapeutics (NASDAQ:MNPR) with a Strong Bu
benzinga.com
Oppenheimer Maintains Outperform on Monopar Therapeutics, Raises Price Target to $115

Oppenheimer analyst Andreas Argyrides maintains Monopar Therapeutics (NASDAQ:MNPR) with a Outperf
benzinga.com
HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $105

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics (NASDAQ: MNPR)
benzinga.com
Piper Sandler Maintains Overweight on Monopar Therapeutics, Raises Price Target to $95

Piper Sandler analyst Biren Amin maintains Monopar Therapeutics (NASDAQ: MNPR) with a Overweight